H.C. Wainwright lowered the firm’s price target on VolitionRx (VNRX) to $1 from $1.50 and keeps a Buy rating on the shares after the company reported Q4 results. The firm, which believes that the company could secure additional human licensing deals in 2026 to help drive topline revenue growth, cites an increased share count for its lowered target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX: